.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Management of high-grade gliomas (HGG) remains one of the most significant challenges in modern oncology. Standard care involving surgery, radiation, and temozolomide often leads to severe, persistent lymphopenia. This reduction in immune cells directly correlates with poorer survival outcomes. Consequently, researchers are investigating novel therapies like NT-I7 for gliomas to restore immune function and improve patient prognosis.
NT-I7 (efineptakin alfa) is a long-acting recombinant human interleukin-7 (IL-7). This cytokine is vital for the development, survival, and homeostasis of lymphocytes. In recent clinical trials, NT-I7 demonstrated the ability to significantly increase absolute lymphocyte counts (ALC) in patients. Therefore, it serves as a critical potential adjunct to standard treatments that typically deplete these cells.
A Phase I clinical trial recently evaluated the safety and efficacy of NT-I7 in newly diagnosed HGG patients. The study determined that NT-I7 is well-tolerated, with a maximum tolerated dose (MTD) of 720 µg/kg. Furthermore, the administration of this therapy resulted in a sustained increase in lymphocyte counts for over 12 weeks. Specifically, it induced a selective expansion of CD8+ T cell clonotypes, which are essential for anti-tumor immunity.
Moreover, the study observed early elevations in CD4+ T cells and NK cells. These changes coincided with increased levels of TNF and CXCL9 cytokines, indicating active immune engagement. Interestingly, patients with MGMT promoter-unmethylated glioblastoma—a subgroup with typically poor prognosis—showed promising clinical responses. This finding suggests that NT-I7 might be particularly beneficial when combined with other immune-based therapies.
The ability of NT-I7 to maintain immune cell populations during aggressive chemoradiotherapy is revolutionary. Because lymphopenia often limits the effectiveness of immunotherapy, reversing this state is a high priority. Currently, researchers are exploring combinations of NT-I7 with checkpoint inhibitors like pembrolizumab. Additionally, further Phase II studies will clarify its impact on overall survival and progression-free survival.
NT-I7 acts as a long-acting IL-7 analog that promotes the proliferation and survival of T cells. It specifically increases absolute lymphocyte counts and expands CD8+ T cell clones to enhance the body\'s immune response against the tumor.
The therapy was generally well-tolerated. Common adverse events included injection site reactions, flu-like symptoms, and fatigue. Dose-limiting toxicities were only noted at higher doses, leading to an MTD of 720 µg/kg.
In clinical evaluations, a single administration of NT-I7 significantly increased absolute lymphocyte counts for a duration exceeding 12 weeks.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
NT-I7 (efineptakin alfa) increases absolute lymphocyte counts and expands CD8+ T cells in high-grade glioma patients, offering a new way to combat lymphopen...
4 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
